Vogt-Koyanagi-Harada (VKH-like) syndrome after administration of nivolumab
DOI:
https://doi.org/10.70313/2718.7446.v15.n04.199Keywords:
Vogt Koyanagi Harada, VKH-like, uveítis, adverse effects, monoclonal antibodies, nivolumabAbstract
Objective: To present a clinical case of Vogt Koyanagi Harada like syndrome due to antineo-plastic therapy with immune checkpoint inhibitors (ICIs) such as nivolumab in a patient with a history of stage III kidney cancer.
Case report: A 67-year-old male patient diagnosed in 2004 with kidney cancer whose initial treatment consisted of surgical resection with satisfactory results, until in 2015 a control comput-ed tomography showed infiltrated lymph nodes. Oncological treatment was started with different antineoplastic drugs belonging to the group of tyrosine kinase inhibitors without obtaining favor-able therapeutic results, so it was decided in 2017 to start treatment with nivolumab (monoclonal antibody). Months later, said drug had to be suspended because the patient presented symptoms compatible with Vogt Koyanagi Harada like after the administration of nivolumab, considering this a serious ophthalmological adverse effect.
Conclusion: In patients treated with nivolumab, ophthalmological control and follow-up is im-portant, given the possible appearance of adverse effects such as VKH-like
Downloads
References
Moorthy RS, Inomata H, Rao NA. Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol 1995; 39: 265-292.
Matsuo T, Yamasaki O. Vogt-Koyanagi-Harada disease-like posterior uveitis in the course of nivolumab (anti-PD-1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma. Clin Case Rep 2017; 5: 694-700.
Baughman DM, Lee CS, Snydsman BE, Jung HC. Bilateral uveitis and keratitis following nivolumab treatment for metastatic melanoma. Med Case Rep (Wilmington) 2017; 3: 8.
Obata S, Saishin Y, Teramura K, Ohji M. Vogt-Koyanagi-Harada disease-like uveitis during nivolumab (anti-PD-1 antibody) treatment for metastatic cutaneous malignant melanoma. Case Rep Ophthalmol 2019; 10: 67-74.
Kikuchi R, Kawagoe T, Hotta K. Vogt-Koyanagi-Harada disease-like uveitis following nivolumab administration treated with steroid pulse therapy: a case report. BMC Ophthalmol 2020; 20: 252.
Dalvin LA, Shields CL, Orloff M et al. Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects. Retina 2018; 38: 1063-1078.
Michot JM, Bigenwald C, Champiat S et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 2016; 54: 139-148.
Zhou YW, Xu Q, Wang Y et al. Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management. Int J Ophthalmol 2022; 15: 646-656.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Consejo Argentino de Oftalmología
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Con esta licencia no se permite un uso comercial de la obra original, ni la generación de obras derivadas. Las licencias Creative Commons permiten a los autores compartir y liberar sus obras en forma legal y segura.
